PhysIQ and Vital Connect study ‘home hospital model’
BOSTON – PhysIQ and Vital Connect are launching an initiative aimed at evaluating how clinician visits to the home, when coupled with continuous patient monitoring, can potentially replace hospitalizations for common medical admissions. The pilot is taking place at Partners HealthCare Brigham and Women’s Hospital. “The evolution of digital medicine makes us even more confident in the home hospital model for our patients,” said Dr. David Levine, the study’s principal investigator, in a statement. “We are in a very exciting era of medicine where clinical-grade biosensors and analytics are capable of delivering continuous physiological insight that was traditionally only available in the hospital environment.” The pilot is the first of two planned initiatives. Patients diagnosed at the BWH Emergency Department with exacerbation of heart failure, pneumonia, COPD, cellulitis or complicated urinary tract infections are provided with a state-of-the-art monitoring solution, including the Vital Connect VitalPatch biosensor that will continuously stream patient vital signs to be analyzed by the physIQ Personalized Physiology Analytics platform. The first phase of the initiative began in the fall and involves up to 60 patients. The pilot will scale up to 500 patients in early 2017.
ColumbiaDoctors chooses HealthGrid for patient engagement
ORLANDO, Fla. – ColumbiaDoctors will use HealthGrid to allow physicians in the multi-specialty practice to connect with their patients through any mobile device.
“This collaboration with HealthGrid is part of our commitment to deepening the patient-provider connection and serving their diverse needs through thoughtful and proactive engagement,” said Dr. George “Jack” Cioffi, president of ColumbiaDoctors, in a statement.
HealthGrid will enable ColumbiaDoctors’ physicians to connect with their patients to provide actionable care coordination, access to critical health information and to enable self-care management.
As part of the initiative, ColumbiaDoctors will fully integrate HealthGrid’s patient engagement platform into its workflow to coordinate care delivery through mobile technology. The platform will allow: pre- and post-visit communications; access to care information to promote collaboration between ColumbiaDoctors’ care teams and care settings; mobile check-in to improve office wait times; personalized patient education to patients’ mobile devices; and instant patient feedback through real-time assessments and surveys.
“We are committed to ensuring that organizations like ColumbiaDoctors have an integrated approach to patient engagement, ensuring patients and care teams are in sync at every care touch point, while also achieving the highest levels of MU (Meaningful Use) attestation for patient-facing measures,” said Raj Toleti, co-founder and CEO of HealthGrid, in a statement.
Insulia receives FDA clearance
CAMBRIDGE, Mass. – Voluntis has received clearance from the U.S. Food and Drug Administration, as well as the CE Mark, for Insulia, a device that supports the management of adult patients with Type 2 diabetes treated with basal insulin. “We look forward to working hand-in-hand with providers and payers, as well as our business partners, to make this innovative solution widely available to patients across the globe,” said Pierre Leurent, Voluntis founder and CEO, in a statement. Insulia is a prescription-only device that provides patients with insulin dose recommendations and educational coaching messages in response to blood glucose values and other diabetes-related data.
Adherium Smartinhaler chosen for study on impact of digital health
MELBOURNE – Adherium’s Smartinhaler has been chosen for the myAirCoach program at different sites in Europe. “The myAirCoach program is a leading initiative assessing the impact that digital health solutions, such as Smartinhaler, can have on patients in a real-world setting,” said Garth Sutherland, founder and Group CEO of Adherium, in a statement. The myAirCoach program was established in 2015 to establish whether or not home monitoring and mobile health systems can be used to reduce asthma the occurrence of asthma exacerbations. One of the main goals of the project is to help patients manage their health through user-friendly tools that will increase awareness of their clinical state, as well as the adherence and effectiveness of the medical treatment they follow. The impact of the myAirCoach program is expected to form the basis for widespread adoption of sensor-based self-management systems across the spectrum of respiratory diseases.
WLSA combines operations with PCHAlliance
SAN DIEGO and WASHINGTON – The Wireless-Life Sciences Alliance (WLSA) and the Personal Connected Health Alliance (PCHAlliance) have combined operations. “WLSA has significant experience addressing issues driving cutting-edge wireless, connected and mobile health research in the engineering, computer science, biomedical and health disciplines,” said Patty Mechael, Ph.D., executive vice president of PCHAlliance, in a statement. “In addition, their focus on medical and health research communities is a perfect complement to our commitment to accelerate the adoption of clinical-grade technology in consumer-friendly health outcomes-based business models.” PCHAlliance has adopted the WLSA membership model, and WLSA’s executive-level engagement and Convergence Summit activities will be integrated in PCHAlliance’s annual Connected Health Conference.
Medtronic partners with Fitbit for diabetes management
DUBLIN and SAN FRANCISCO – Medtronic and Fitbit are working together to integrate health and activity tracking for patients living with diabetes, and their physicians and care teams. The iPro2 myLog mobile app will allow Type 2 diabetes patients to see their glucose levels and physical activity data in one streamlined app. “By creating a connection between physical activity and glucose levels, our iPro2 myLog mobile app solution provides new tools and insights, so that physicians can optimize therapy and patients can better understand how to manage their diabetes,” said Laura Stoltenberg, vice president and general manager of Non-Invasive Diabetes Therapies at Medtronic, in a statement.
Reliq Health launches pain management pilot
VANCOUVER – Reliq Health Technologies has begun enrolling patients in the pilot of its remote patient monitoring and secure communication solution with The Feldman Institute in Baton Rouge, Louisiana. The pilot will evaluate the use of Reliq Health’s technology with patients who have been discharged home after interventional pain management surgery, or have returned to their homes between treatments at the Institute. “Our virtual care solution allows patients to receive high quality follow-up care from the comfort of their own homes,” said Dr. Lisa Crossley, CEO of Reliq Health, in a press release. Patients can communicate with their care team at The Feldman Institute using Reliq’s cloud-based secure messaging, videoconferencing and virtual visits.
SocialWellth launches curated app boutique
LAS VEGAS – Digital health company SocialWellth wants to help consumers manage their mobile health apps with Happtique, a curated app boutique. “Our intelligence-driven curation process, used for all apps in Happtique, consistently finds, organizes, interprets and shares the most relevant and highest quality mobile health apps across 48 health, balanced living and lifestyle categories,” said David Vinson, SocialWellth founder and CEO. The Happtique program evaluates and filters mHealth apps for relevance, value, user ratings, scientific evidence and consumer engagement. Each curated app undergoes a rigorous review, beginning with an Adaptive Privacy and Security scan. Each app also has an App Curation, Usability and Testing scorecard. Using quick-polls and other data capturing techniques, Happtique initiates a digital dialog with consumers to gain insights, and the user interface is linked to social networking accounts. “We take our enterprise-level curation process, leveraging experts and an established set of industry guidelines, to create a personalized mini app boutique around a consumer’s own goals and interests,” said Vinson.
LifeScan, BlueStar integration receives FDA clearance
CHESTERBROOK, Penn. – The U.S. Food and Drug Administration has given clearance to a diabetes management solution that integrates LifeScan’s OneTouch Verio Flex blood glucose monitoring system with WellDoc Inc.’s clinically validated management platform, BlueStar. The new solution will provide patients with Type 2 diabetes with individualized real-time feedback and virtual coaching based on the patient’s specific treatment plan, and also help health care teams make timely diabetes management decisions. The OneTouch Verio Flex meter also has optional wireless connectivity with the OneTouch Reveal mobile app. LifeScan and WellDoc are currently working with health plans to help provide patient access to the integrated system.
Noom bases pricing model on outcomes
NEW YORK – Mobile health coaching provider Noom has tied its pricing model to outcomes.
“We truly care about preventing and reversing chronic conditions,” said Saeju Jeong, Noom CEO and co-founder, in a statement. “That’s why we’ve strengthened our commitment to behavior change and real health outcomes by only charging customers when we successfully deliver results.”
Noom’s mobile health platform combines technology with live coaching to change the behavior associated with lifestyle-induced pre-chronic and chronic conditions.
With the new pricing model, Noom’s diabetes prevention program will only charge when someone loses at least 5% of their body weight. The company’s hypertension and pre-hypertension program will only charge when someone improves their blood pressure or diagnostic category, and the diabetes management program will only charge when someone improves their blood sugar or diagnostic category.
“I know from the 50 million times our users have weighed in, checked their blood sugar or logged their blood pressure that our programs deliver successful outcomes like clockwork,” said Jeong. “At Noom, we’re willing to put our money where our mouth is.”
Arthro Therapeutics raises $2.2M
MALMO, Sweden – Startup Arthro Therapeutics will use $2.2 million in funding to continue developing its flagship product, Joint Academy, a digital evidence-based intervention program for people with osteoarthritis.
“We have shown that we deliver clinical proof and outcomes equivalent to traditional face-to-face treatments, but with half the resources,” said Jakob Dahlberg, CEO and co-founder of Arthro Therapeutics, in a statement.
Joint Academy is a digitized version of the Swedish evidence-based program Better Management of Osteoarthritis, which has been completed by more than 60,000 patients.
By transferring the medical protocol to a digital context and mining BOA data gathered over the years, Arthro created a proprietary treatment addressing people with joint pain.
The clinical outcomes have enabled Arthro to capture 40% of the private health insurance market for osteoarthritis in Sweden, covered by major health plans.
“This is something we have managed to reproduce with hundreds of patients, and with the new round of funding, we will be able to bring our program to thousands of patients,” said Dahlberg. “Medicine transformed into software through data science is something we believe will become ubiquitous in the clinical workflow.
One Drop gets FDA clearance for One Drop/Chrome
NEW YORK – One Drop has received clearance from the U.S. Food and Drug Administration, as well as CE Mark approval, for the One Drop/Chrome, a blood glucose monitoring system.
“One Drop is designed by people with diabetes for people with diabetes, and One Drop/Chrome is a perfect embodiment of our vision,” said Jeff Dachis, One Drop CEO and founder, in a statement.
One Drop/Chrome is available as part of One Drop/Premium, the first monthly subscription service to provide affordable, accessible diabetes care, unlimited blood glucose testing supplies and 24/7 live in-app support.
With One Drop/Mobile’s seamless user experience and deep data integration, users have contributed more than 100 million health data points, logging in more than 2 million times to the app, which tracks blood glucose, medication, food and physical activity.
A recent analysis of data showed that users: consistently tracked their food and blood glucose over time; increased their average number of in-range blood glucose readings by 40%; reduced their average percentage of high blood glucose readings from 18.5% to 3.7%; and reduced their average blood glucose value from 185 mg/dL to 158 mg/dL.
“We’re transforming the diabetes management experience by designing empowering, beautiful products people love to use while also delivering outstanding evidence-based results,” said Dachis.